Title:High Plasmatic Levels of Advanced Glycation End Products are Associated with Metabolic Alterations and Insulin Resistance in Preeclamptic Women
Volume: 20
Issue: 9
Author(s): Elizabeth García-Gómez, Mariana Bobadilla-Bravo, Eulises Díaz-Díaz, Edgar Ricardo Vázquez-Martínez, Sonia Nava-Salazar, Yessica Torres-Ramos, Carmen Selene García-Romero, Ignacio Camacho-Arroyo and Marco Cerbón*
Affiliation:
- Unidad de Investigacion en Reproduccion Humana, Instituto Nacional de Perinatologia-Facultad de Quimica, Universidad Nacional Autonoma de Mexico,Mexico
Keywords:
preeclampsia, advanced glycation end products, liver enzymes, uric acid, glucose, insulin resistance.
Abstract:
Aims: The purpose of this study was to investigate the association between
plasmatic levels of advanced end glycation products (AGEs) and the metabolic profile in
subjects diagnosed with preeclampsia, due to the known relation of these molecules with
oxidative stress and inflammation, which in turn are related with PE pathogenesis.
Background: It has been reported that increased levels of AGEs are observed in patients
with preeclampsia as compared with healthy pregnant subjects, which was mainly
associated with oxidative stress and inflammation. Besides, in women with preeclampsia,
there are metabolic changes such as hyperinsulinemia, glucose intolerance, dyslipidemia,
among others, that are associated with an exacerbated insulin resistance. Additionally,
some parameters indicate the alteration of hepatic function, such as increased levels of liver
enzymes. However, the relationship of levels of AGEs with altered lipidic, hepatic, and
glucose metabolism parameters in preeclampsia has not been evaluated.
Objective: To investigate the association between plasmatic levels of AGEs and hepatic,
lipid, and metabolic profiles in women diagnosed with preeclampsia.
Methods: Plasma levels of AGEs were determined by a competitive enzyme-linked
immunosorbent assay (ELISA) in 15 patients diagnosed with preeclampsia and 28
normoevolutive pregnant subjects (control group). Hepatic (serum creatinine, gammaglutamyl
transpeptidase, aspartate transaminase, alanine transaminase, uric acid, and
lactate dehydrogenase), lipid (apolipoprotein A, apolipoprotein B, total cholesterol,
triglycerides, low-density lipoproteins, and high-density lipoproteins), and metabolic
variables (glucose, insulin, and insulin resistance) were assessed.
Results: Plasmatic levels of AGEs were significantly higher in patients with preeclampsia
as compared with the control. A positive correlation between circulating levels of AGEs and
gamma-glutamyl transpeptidase, uric acid, glucose, insulin, and HOMA-IR levels was found
in patients with preeclampsia. In conclusion, circulating levels of AGEs were higher in
patients with preeclampsia than those observed in healthy pregnant subjects. Besides,
variables of hepatic and metabolic profile, particularly those related to insulin resistance,
were higher in preeclampsia as compared with healthy pregnant subjects. Interestingly,
there is a positive correlation between AGEs levels and insulin resistance.
Conclusions: Circulating levels of AGEs were higher in patients with preeclampsia than
those observed in healthy pregnant subjects. Besides, hepatic and metabolic profiles,
particularly those related to insulin resistance, were higher in preeclampsia as compared
with healthy pregnant subjects. Interestingly, there is a positive correlation between AGEs
levels and insulin resistance, suggesting that excessive glycation and an impaired
metabolic profile contribute to the physiopathology of preeclampsia.
